Possible to buy KX-826 in Europe?
    Product 7/28/2024

    New to KX-826? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this question or advice post, the primary subjects mentioned are the tone is 😐 neutral.

    Other terms

    KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

      community GT20029 & KX826 Major Updates from Kintor.

       101 upvotes 1 year ago
      KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

      community Kintor KX-826 Discounts (and is the 0.9% more effective)?

       5 upvotes 10 months ago
      Kintor KX-826, a hair loss treatment, is being discussed for its pricing and effectiveness, with a focus on whether the 0.9% concentration is more effective than the 0.5%. Users are seeking cheaper purchasing options.

      community Results of the Kintor KX-826 group buy?

       11 upvotes 4 years ago
      People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

      community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

       17 upvotes 4 years ago
      People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

    Related Research

    6 / 6 results
      Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

      research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

      1 citations , April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences”
      This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
      A Decade of Progress in Androgenetic Alopecia Management: Emerging Therapies and Multimodal Strategies

      research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies

      December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology”
      This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Androgenetic Alopecia: Therapy Update

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.